Vildasmart Tablet (Dapagliflozin + Metformin + Vildagliptin)
Vildasmart Tablet combines dapagliflozin, metformin, and vildagliptin in a single oral formulation designed for the improved management of type 2 diabetes mellitus. This triple-mechanism therapy is specifically tailored for patients who need enhanced glycemic control beyond monotherapy or dual therapy.
Introduction
What it is:
Vildasmart Tablet is a triple-combination antidiabetic medication formulated with dapagliflozin, metformin, and vildagliptin. Designed for adults with type 2 diabetes mellitus, this tablet is intended when lifestyle interventions and single- or dual-agent therapies do not provide adequate glycemic control.
Who it's for:
Adults with type 2 diabetes inadequately managed by monotherapy or dual therapy, and in need of enhanced glycemic control, especially when weight management, cardiovascular, and kidney benefits are also desired.
Precautions
- Contraindications:
- Type 1 diabetes, diabetic ketoacidosis, severe kidney or liver disease.
- Kidney impairment: Use with caution — risk of lactic acidosis increases; dose adjustment may be necessary.
- Liver disease, dehydration, infection, or surgery: Inform your doctor before starting treatment.
- Pregnant or breastfeeding women: Use only if clearly needed and after consulting a healthcare professional.
- Elderly patients: Monitor closely for volume depletion and renal function decline.
- Alcohol: Avoid excessive intake to reduce risk of hypoglycemia and lactic acidosis.
Uses
- Management of Type 2 Diabetes Mellitus in adults.
- Improves blood sugar control, helps reduce long-term diabetic complications, supports weight and metabolic control, and offers cardiovascular and renal protection.
Side Effects
Common Side Effects
- Urinary tract infections, vaginal yeast infections, nasopharyngitis (upper respiratory tract infection).
- Nausea, diarrhea, headache, vomiting, frequent urination (polyuria), back pain, dizziness.
Serious / Rare Side Effects
- Hypoglycemia (especially when co-administered with other antidiabetics).
- Lactic acidosis (rare, associated with metformin accumulation, particularly in renal impairment).
- Volume depletion, dehydration, and hypotension due to osmotic diuresis from dapagliflozin.
- Genital infections, urinary tract infections, including serious cases like Fournier’s gangrene (rare) .
- Diabetic ketoacidosis (rare but serious, especially around surgery).
FAQs
Q: Is Vildasmart safe for kidney health?
Use with caution in renal impairment; risk of lactic acidosis exists—consult your doctor for dose adjustments.
Q: What should I do if I forget a dose?
Take as soon as you remember. If it’s almost time for the next dose, skip the missed one. Do not double up.
Q: Can I take it with or without food?
Yes—follow your doctor's advice, though taking with meals may reduce gastric discomfort .
Q: Is it suitable for weight management?
Yes—dapagliflozin can support modest weight loss via increased urinary glucose excretion.
Q: Can it reduce the risk of heart and kidney complications?
Yes—dapagliflozin with metformin has demonstrated cardiovascular and renal benefits beyond glucose control.
Q: Is it used for type 1 diabetes?
No—this combination is not indicated for type 1 diabetes or diabetic ketoacidosis.
Interactions
- Iodinated contrast agents: May precipitate lactic acidosis when used with metformin—temporary discontinuation is advised around imaging procedures.
- CYP3A4 inducers (e.g., rifampicin): May reduce vildagliptin’s effectiveness .
- Metformin interactions: Risk of increased levels when co-administered with cationic drugs such as digoxin, trimethoprim.
- Lithium: Dapagliflozin may reduce serum lithium — monitor levels.
- Diuretic drugs, antihypertensives, or NSAIDs: May increase risk of hypovolemia or renal decline — monitor closely.
| Manufacturer | : | Healing Pharma |
| Trade Name | : | |
| Generic Search | : | Dapagliflozin + Metformin + Vildagliptin |
| Strength | : | 10/500/100, 10/100/1000 |
Latest Products
